Announcement • Dec 11

Marinus Pharmaceuticals Receives Nasdaq Bid Price Deficiency Notice

On December 6, 2024, Marinus Pharmaceuticals, Inc. (the Company") received written notice (the Bid Price Deficiency Notice") from The Nasdaq Stock Market, LLC (Nasdaq") notifying the Company that for the previous 30 consecutive business days, the bid price for the Company's common stock, par value $0.001 (the Common Stock"), had closed below the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Global Market, as set in Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Price Requirement"). The Bid Price Deficiency Notice has no effect at this time on the listing of the Common Stock, which continues to trade on The Nasdaq Global Market under the symbol MRNS". In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until June 4, 2025 (the Bid Price Compliance Date"), to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement, the closing bid price of the Common Stock must be at least $1.00 per share for a minimum of 10 consecutive business days during the 180-day compliance period. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Bid Price Compliance Date, the Company may be eligible for a second 180 calendar day compliance period. To qualify for this additional compliance period, the Company must submit an application to transfer to The Nasdaq Capital Market (the Capital Market"), provided that it meets the market value of publicly held shares requirement for continued listing on the Capital Market and all other applicable requirements for initial listing on the Capital Market, other than the Capital Market's bid price requirement. The Company would also need to pay an application fee and provide written notice to Nasdaq of its intention to cure the deficiency during the additional compliance period. As part of its review process to determine whether the additional compliance period is afforded to the Company, Nasdaq will make a determination of whether it believes the Company will be able to cure this deficiency. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting. At such time, the Company may appeal the delisting determination to a Nasdaq hearing panel. Also on December 6, 2024, the Company received written notice (the Market Value of Listed Securities Deficiency Notice") from Nasdaq notifying the Company that for the previous 30 consecutive business days, the market value of the Common Stock remained below the $50.0 million minimum market value of listed securities requirement for continued listing on The Nasdaq Global Market, as set in Nasdaq Listing Rule 5450(b)(2)(A) (the MVLS Requirement"). The Market Value of Listed Securities Deficiency Notice has no effect at this time on the listing of the Common Stock, which continues to trade on The Nasdaq Global Market under the symbol MRNS". In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has a period of 180 calendar days, or until June 4, 2025 (the MVLS Compliance Date"), to regain compliance with the MVLS Requirement. To regain compliance with the MVLS Requirement, the market value of the Common Stock must close at $50.0 million or more for a minimum of 10 consecutive business days during the 180-day compliance period. If the Company does not regain compliance with the MVLS Requirement by the MVLS Compliance Date, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Common Stock will be subject to delisting. At such time, the Company may appeal the delisting determination to a Nasdaq hearing panel. Alternatively, the Company may submit an application and pay the related fee to transfer to the Capital Market to take advantage of the Capital Market's listing requirements, provided that it then satisfies the applicable requirements for continued listing on the Capital Market. The Company intends to actively monitor the minimum bid price and the market value of the Common Stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement and the MVLS Requirement. There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement, the MVLS Requirement or maintain compliance with any other listing requirements.

Marinus Pharmaceuticals, Inc. Stock Price

MRNS Share Price Performance

MRNS Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Marinus Pharmaceuticals, Inc. Key Details

About MRNS

Recent MRNS News & Updates

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from NASDAQ Composite Index

Immedica Pharma AB entered into an agreement to acquire Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS) for $31 million.

Marinus Pharmaceuticals Receives Nasdaq Bid Price Deficiency Notice

Recent updates

Marinus Pharmaceuticals, Inc. Competitors

Nordicus Partners

OKYO Pharma

Zhengye Biotechnology Holding

Cingulate